20 July 2020

Versameb AG has closed a CHF 6 million seed financing round. Versameb is engaged in the discovery and development of next-generation RNA-based drugs using its proprietary VERSagile technology platform developing molecules targeting regulation of immune response or regeneration in the fields of dermatology, oncology and myology.

VISCHER AG advises Versameb with Matthias Staehelin, Moritz Jäggy and Dania Salvisberg-Schneider (all Corporate).

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital

You are currently offline. Some pages or content may fail to load.